Pharmaceutical - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

1 to 25 of 320 results

FDA approves fourth hepatitis C drug, AbbVie’s Viekira Pak

FDA approves fourth hepatitis C drug, AbbVie’s Viekira Pak

20-12-2014

The US Food and Drug Administration on Friday confirmed the much anticipated approval of US pharma company…

AbbVieAnti-viralsPharmaceuticalRegulationUSAViekira Pak

GSK shingles vaccine candidate meets Ph III primary endpoint

GSK shingles vaccine candidate meets Ph III primary endpoint

18-12-2014

UK pharma major GlaxoSmithKline today released pivotal Phase III study data to assess the efficacy of…

AgenusAnti-viralsGlaxoSmithKlineHZ/suPharmaceuticalResearchVaccines

China's Ebola vaccine enters clinical trials

China's Ebola vaccine enters clinical trials

18-12-2014

An Ebola vaccine developed by a military-tied research institute has been approved to enter the human…

Anti-viralsChinaPharmaceuticalResearchVaccines

Sanofi Pasteur gains FDA approval of Fluzone Intradermal Quadrivalent for adults

Sanofi Pasteur gains FDA approval of Fluzone Intradermal Quadrivalent for adults

13-12-2014

French pharma major Sanofi’s vaccines division, Sanofi Pasteur, has received approval from the US Food…

Anti-viralsFluzonePharmaceuticalRegulationSanofiSanofi PasteurUSAVaccines

Merck and NewLink Ebola vaccine trial suspended as patients report joint pain

Merck and NewLink Ebola vaccine trial suspended as patients report joint pain

12-12-2014

Pharma giant Merck & Co’s Phase I trial of Ebola Vaccine VSV-ZEBOV, developed in conjunction with NewLink,…

Anti-viralsMerck & CoNewLink GeneticsPharmaceuticalResearchSwitzerland

Big savings on HIV drugs via pooled procurement expected by Global Fund

Big savings on HIV drugs via pooled procurement expected by Global Fund

12-12-2014

The Global Fund to Fight AIDS, Tuberculosis and Malaria is putting into place a new agreement for purchasing…

Anti-viralsFinancialGlobalHealthcarePharmaceuticalPricing

Effective malaria control dramatically reduces deaths, but challenges remain, report warns

Effective malaria control dramatically reduces deaths, but challenges remain, report warns

09-12-2014

Effective malaria control has dramatically reduced the number of people dying from the disease since…

Anti-viralsAntibiotics and Infectious diseasesPharmaceuticalResearchRest of the World

Russia may face a shortage of drugs against HIV

Russia may face a shortage of drugs against HIV

02-12-2014

Russia may face a shortage of drugs against HIV, due to disruptions of state auctions for the public…

Anti-viralsHealthPharmaceuticalProductionRussia

Merck Ebola vaccine is well-tolerated by volunteers in early trials

Merck Ebola vaccine is well-tolerated by volunteers in early trials

02-12-2014

The Ebola vaccine developed by pharma giant Merck & Co and NewLink has been well-tolerated by trial volunteers…

Anti-viralsMerck & CoNewLink GeneticsPharmaceuticalResearch

Two batches of Novartis' Fluad taken off market for investigation in Italy after 13 deaths

Two batches of Novartis' Fluad taken off market for investigation in Italy after 13 deaths

01-12-2014

The Italian Medicines Agency (AIFA) has suspended two batches of Swiss drug major Novartis’ Fluad seasonal…

Anti-viralsFluadItalian Medicines AgencyItalyNovartisPharmaceuticalRegulation

AbbVie signs agreement with Medicines Patent Pool for lopinavir and retonavir in pediatric HIV

AbbVie signs agreement with Medicines Patent Pool for lopinavir and retonavir in pediatric HIV

01-12-2014

US drugmaker AbbVie and the Medicines Patent Pool have agreed a licensing agreement for lopinavir and…

AbbVieAnti-viralsLopinavirPharmaceuticalResearchRitonavir TabletsUSA

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

27-11-2014

US pharma major Bristol-Myers Squibb has received a Complete Response Letter from the US Food and Drug…

Anti-viralsBristol-Myers SquibbdaclatasvirPharmaceuticalRegulationUSA

Early results from GSK and NIH's Phase I Ebola vaccine show promise

Early results from GSK and NIH's Phase I Ebola vaccine show promise

27-11-2014

UK pharma major GlaxoSmithKline has reported promising preliminary results from a small Phase I trial…

Anti-viralsEbola vaccineGSKPharmaceuticalResearch

HIV therapy Rezolsta approved by EC

HIV therapy Rezolsta approved by EC

25-11-2014

Belgium-based Janssen-Cilag International NV, a subsidiary of US health care giant Johnson & Johnson,…

Anti-viralsEuropeJanssen-CilagPharmaceuticalPrezistaRegulation

EMA unit backs new hep C drugs Exviera and Viekirax from AbbVie

EMA unit backs new hep C drugs Exviera and Viekirax from AbbVie

21-11-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

AbbVieAnti-viralsEuropeExvieraPharmaceuticalRegulationViekirax

European Union's response to Ebola emergency

18-11-2014

West Africa is currently facing the largest and most complex Ebola epidemic on record. Guinea, Liberia…

Anti-viralsFinancialPharmaceuticalResearchRest of the WorldTropical diseases

Roche drops rights to Inovio’s prostate cancer candidate

17-11-2014

Swiss pharma major Roche has terminated its 2013 collaboration, option, and license agreement with US…

Anti-viralsFinancialINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

New data show strong cure rates with AbbVie’s hep C therapy in HIV and transplant patient studies

New data show strong cure rates with AbbVie’s hep C therapy in HIV and transplant patient studies

11-11-2014

US pharma company AbbVie got a boost for its upcoming hepatitis C treatment regimen, with the company…

AbbVieAnti-viralsPharmaceuticalResearchUSA

Merck’s triple-therapy hepatitis C regimen shows sub-optimal efficacy

Merck’s triple-therapy hepatitis C regimen shows sub-optimal efficacy

11-11-2014

US pharma giant Merck & Co has admitted that interim data from its triple-therapy regimen in hepatitis…

Anti-viralsHCVHepatitis CHepatitis C virusMerck & CoPharmaceuticalResearchsofosbuvirUSA

EFPIA and IMI launch 280 million-euro Ebola program, calling for proposals

EFPIA and IMI launch 280 million-euro Ebola program, calling for proposals

10-11-2014

The European Federation of Pharmaceutical Industries and Associations, its specialized group Vaccines…

Anti-viralsEuropeFinancialPharmaceuticalResearchUSA

Sanofi reports positive data in Phase III dengue vaccine trial, with 95.5% efficacy against severe dengue

Sanofi reports positive data in Phase III dengue vaccine trial, with 95.5% efficacy against severe dengue

04-11-2014

French drug major Sanofi has reported positive data with its experimental tetravalent dengue vaccine…

Anti-viralsFrancePharmaceuticalResearchSanofi Pasteur

1 to 25 of 320 results

Back to top